Journal ArticleDOI
Current Trends in Virtual High Throughput Screening Using Ligand-Based and Structure-Based Methods
Reads0
Chats0
TLDR
Recent developments in the methodology and applications of structure-based and ligand-based methods and target-based chemogenomics in Virtual High Throughput Screening (VHTS) are reviewed, highlighting some case studies of recent applications, as well as current research in further development of these methods.Abstract:
High throughput in silico methods have offered the tantalizing potential to drastically accelerate the drug discovery process. Yet despite significant efforts expended by academia, national labs and industry over the years, many of these methods have not lived up to their initial promise of reducing the time and costs associated with the drug discovery enterprise, a process that can typically take over a decade and cost hundreds of millions of dollars from conception to final approval and marketing of a drug. Nevertheless structure-based modeling has become a mainstay of computational biology and medicinal chemistry, helping to leverage our knowledge of the biological target and the chemistry of protein-ligand interactions. While ligand-based methods utilize the chemistry of molecules that are known to bind to the biological target, structure-based drug design methods rely on knowledge of the three-dimensional structure of the target, as obtained through crystallographic, spectroscopic or bioinformatics techniques. Here we review recent developments in the methodology and applications of structure-based and ligand-based methods and target-based chemogenomics in Virtual High Throughput Screening (VHTS), highlighting some case studies of recent applications, as well as current research in further development of these methods. The limitations of these approaches will also be discussed, to give the reader an indication of what might be expected in years to come.read more
Citations
More filters
Journal ArticleDOI
Prospective evaluation of shape similarity based pose prediction method in D3R Grand Challenge 2015
Ashutosh Kumar,Kam Y. J. Zhang +1 more
TL;DR: Overall, the D3R Grand Challenge 2015 results demonstrated that ligand 3D shape similarity with the crystal ligand is sufficient to predict binding poses of new ligands with acceptable accuracy.
Journal ArticleDOI
Diversity and Chemical Library Networks of Large Data Sets.
Timothy B. Dunn,Gustavo M. Seabra,Taewon David Kim,K. Eurídice Juárez-Mercado,Chenglong Li,José L. Medina-Franco,Ramón Alain Miranda-Quintana +6 more
TL;DR: The Chemical Library Networks (CLNs) as mentioned in this paper are a general and efficient framework to represent visually the chemical space of large chemical libraries providing a global perspective of the relation between the libraries. And they can be explored with any structure representation and similarity coefficient.
Journal ArticleDOI
Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase
TL;DR: A cost-effective method called "pathway docking" was used to screen ligand-receptor binding free energy surface to reveal possible paths of ligand approaching protein binding pocket, and the equilibrium pathways identified are found to be similar to those identified in prior studies using highly expensive computational approaches.
Journal ArticleDOI
QSAR methods for the discovery of new inflammatory bowel disease drugs
Ramón García-Domenech,Maria Galvez-Llompart,Riccardo Zanni,María del Carmen Recio,Jorge Galvez +4 more
TL;DR: This review aims to provide the most recent and important advances of in silico IBD drug discovery by focusing on QSAR methods, especially those based on molecular topology (MT), which has proven successful in other drug discovery.
Journal ArticleDOI
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
TL;DR: To reveal novel insights into the inhibition of BCR-ABL tyrosine kinase, pharmacophore mapping studies were performed for a series of phenylaminopyrimidine-based (PAP) derivatives, including imatinib (Gleevec).